109 Darid Datiota

Form PTO-1390

U.S. DEPARTMENT OF COMMERCE ATTORNEY'S DOCKE PATENT AND TRADEMARK OFFICE

P29865

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

International Application as filed in Japanese.

PCT/ISA/237 (in Japanese).

PCT/IB/301. PCT/IB/304. PCT/IB/308 (2). Claim of Priority.

PCT/RO/101 PCT Request and Fee Calculation Sheet (in Japanese). PCT/ISA/210 International Search Report (in English and Japanese).

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/JP2004/016363 28 October 2004 29 October 2003 TITLE OF INVENTION MEDICAMENT FOR THERAPEUTIC AND/OR PREVENTIVE TREATMENT OF RESTENOSIS OR REOCCLUSION AFTER VASCULAR RECANALIZATION OPERATION APPLICANT(S) FOR DO/EO/US Koichi SHUDO, Akiko ITAI, and Susumu MUTO Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information. 1. A This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. 🖾 This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below. 4. The US has been elected (PCT Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. \(\overline{\Omega}\) is attached hereto (required only if not communicated by the International Bureau). b. A has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). a.

 is attached hereto. b. has been previously submitted under 35 U.S.C. 154 (d) (4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a.

are attached hereto (required only if not communicated by the International Bureau). b. \square have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. .371(c)(4)). "Unexecuted" 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 22 below concern other document(s) or information included: 11. Assignee: Koichi SHUDO, of Tokyo, Japan; and Institute of Medicinal Molecular Design. Inc., of Tokyo, Japan 12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 15. An Application Data Sheet under 37 C.F.R. 1.76. A substitute specification. 17.

A power of attorney and/or change of address letter. 18.

Figure of Drawing to be published: 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 20. A second copy of the published international application under 35 U.S.C. 154 (d) (4). 21. A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4). 22. Other items or information: Cover Letter under 35 U.S.C. 371 and 37 C.F.R. 1.495. International Application as published in Japanese.

REGISTRATION NUMBER

(703) 716-1191

P29865.P02

St 544487 AP20 REC'UPETIETO 27 APR 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Koichi SHUDO et al.

Mail Stop PCT

Appl. No.: Not Yet Assigned (U.S. National Phase of PCT/JP2004/016363)

I.A. Filed: October 28, 2004

For

: MEDICAMENT FOR THERAPEUTIC AND/OR PREVENTIVE TREATMENT

OF RESTENOSIS OR REOCCLUSION AFTER VASCULAR

RECANALIZATION OPERATION

COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT APPLICATION FILED UNDER 35 U.S.C. 371 AND 37 C.F.R. 1.495

Mail Stop PCT

Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window, Mail Stop PCT Randolph Building **401 Dulany Street** Alexandria, VA 22314

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to the above, this application should be associated with Customer Number 07055, which includes the present correspondence address as follows:

> GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191

30/577487 (AP20Rec'd PCT/PTO 27 APR 2006

P29865.P02

If there are any questions pertaining to this National Stage Application, please contact the undersigned.

Respectfully submitted, Koichi SHUDO et al.

Bruce H. Bernstein Reg. No. 29,027 Leslie J. Paperner Reg. #33329

April 26, 2006 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191